表紙
市場調查報告書
商品編碼
1036267

液體活檢市場:按癌症、按用途、按生物標誌物、按位置、按產品以及價格和數量展望(2022-2026 年)

Liquid Biopsy Markets By Cancer, Usage, Biomarker, Place, & Product With Price And Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2022-2026

出版日期: | 出版商: Howe Sound Research | 英文 510 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介
該報告調查了全球液體活檢市場,提供了市場概況以及癌症、使用、生物標誌物、位置、產品、地區和進入市場的公司概況的趨勢。

目錄

第 1 章市場指南

  • 液體活檢市場——COVID-19 的戰略形勢邏輯和影響
  • 高管、營銷、銷售和業務發展人員指南
  • 管理顧問和投資顧問指南

第二章市場的介紹和定義

  • 什麼是液體活檢?
  • 測序革命
  • 市場定義
    • 收入市場規模
  • 調查方法
    • 作者
    • 來源
  • 展望:醫療保健、IVD 行業和 COVID-19 大流行

第 3 章市場概覽

  • 充滿活力的市場參與者
    • 學術實驗室
    • 診斷測試開發人員
    • 基因組儀器供應商
    • 醫藥/試劑供應商
    • 獨立實驗室
    • 公共國家/地區實驗室
    • 醫院實驗室
    • 臨床實驗室
    • 審計機構
    • 認證機構
  • 活檢的使用
    • 癌症
    • 癌前病變
    • 炎症症狀
  • 活檢部位
  • 今天的情況-活檢分析
  • 癌症液體活檢技術的證據
  • 靶向癌症治療方案
  • 產業結構發揮作用

第 4 章市場趨勢

  • 生長促進劑
    • 非侵入性遊戲規則改變者
    • 降低成本
    • 提高準確性
    • 廣泛的潛在用途
    • 老齡人口
  • 生長抑製劑
    • 低價
    • 缺乏標準
    • 協議抵抗
    • 初始安裝成本
    • COVID-19
  • 設備和自動化
    • 市場份額的關鍵設備
    • 生物信息學發揮作用
  • 診斷技術的發展
    • 新一代測序推動革命
    • NGS 對定價的影響
    • 藥理學基因組學掩蓋了診斷和治療
    • CGES 測試,勇敢的新世界
    • 基於生物芯片/巨磁阻的檢測

第 5 章液體活檢的最新發展

第 6 章關鍵廠商簡介

  • Abbott Diagnostics
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • bioM?rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid(now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health(Beijing)Co., Ltd.
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

第 7 章液體活檢診斷的全球市場

  • 按國家/地區分列的世界市場概覽
  • 全球市場概覽,作者:Cancer
  • 世界市場概覽,按用途
  • 世界市場概覽,按地點
  • 全球市場概覽,作者:Marker
  • 全球市場概覽,按產品

第 8 章全球液體活檢診斷市場-癌症

  • 乳腺癌
  • 結直腸癌
  • 宮頸癌
  • 肺癌
  • 前列腺癌
  • 其他

第 9 章全球液體活檢診斷市場-按使用情況

  • 篩選
  • 診斷
  • 治療
  • 監視器

第 10 章液體活檢診斷的全球市場-按位置

  • 醫院實驗室
  • 實驗室服務
  • 門診實驗室
  • 其他

第 11 章全球液體活檢診斷市場-按標記

  • 循環腫瘤細胞
  • 無細胞 DNA
  • 囊泡
  • 其他

第 12 章全球液體活檢診斷市場-副產品

  • 套件
  • 設備
  • 服務

第 13 章附錄

  • 美國醫療保險系統:2021 年實驗室費用表
目錄

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What is Liquid Biopsy?
  • 2.2 The Sequencing Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Genomic Instrumentation Supplier
      • 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4 Pharmaceutical/Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 Using Biopsies
    • 3.2.1 Cancer
    • 3.2.2 Precancerous conditions
    • 3.2.3 Inflammatory conditions
  • 3.3 Biopsy Sites
  • 3.4 The Situation Today - Biopsy Analysis
  • 3.5 Evidence of Cancer - Liquid Biopsy Technology
    • 3.5.1 The Big Picture on Liquid Biopsy Technology
    • 3.5.2 The Role of CTCs
      • 3.5.2.1 Types of CTCs
      • 3.5.2.2 CellSearch Detection- Ultimate Sensitivity
      • 3.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
      • 3.5.2.4 Maintrac Detection - The Microscope
      • 3.5.2.5 Other Methods
    • 3.5.3 ctDNA - Going Mainstream?
    • 3.5.4 Exosomes and Micro Vesicles - New Kid on the Block
    • 3.5.5 The Multiple Play
  • 3.6 Cancer Treatment Protocol Under Siege
    • 3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 3.6.2 The Cancer Screening Market Opportunity
      • 3.6.2.1 GRAIL - What Is It?
    • 3.6.3 Cancer Management vs. Diagnosis
      • 3.6.3.1 The Role of Risk Assessment
      • 3.6.3.2 Managing Therapy
      • 3.6.3.3 Monitoring Disease - What Is It?
    • 3.6.4 Phases of Adoption - Looking into The Future
    • 3.6.5 The Promise of Liquid Biopsy
  • 3.7 Structure of Industry Plays a Part
    • 3.7.1 Hospital Testing Share
    • 3.7.2 Economies of Scale
      • 3.7.2.1 Hospital vs. Central Lab
    • 3.7.3 Physician Office Lab's
    • 3.7.4 Physician's and POCT

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Non Invasive Game Changer
    • 4.1.2 Lower Cost
    • 4.1.3 Greater Accuracy
    • 4.1.4 Wide Range of Potential Uses
    • 4.1.5 Aging Population
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower prices
    • 4.2.2 Lack of Standards
    • 4.2.3 Protocol Resistance
    • 4.2.4 Initial Adoption Cost
    • 4.2.5 COVID-19
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 Bioinformatics Plays a Role
  • 4.4 Diagnostic Technology Development
    • 4.4.1 Next Generation Sequencing Fuels a Revolution
    • 4.4.2 Impact of NGS on pricing
    • 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4 CGES Testing, A Brave New World
    • 4.4.5 Biochips/Giant magneto resistance based assay

5 Liquid Biopsy Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 Invitae to Expand Cancer Testing Portfolio
  • 5.3 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
  • 5.4 IVBH Bio Takes Aim at With Liquid Biopsy Incubator
  • 5.5 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
  • 5.6 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
  • 5.7 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
  • 5.8 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
  • 5.9 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
  • 5.10 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
  • 5.11 Bio-Techne to Acquire Asuragen for up to $320M
  • 5.12 Personalis Broadens Liquid Biopsy Offering
  • 5.13 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
  • 5.14 Delfi Diagnostics Plans Multi-Cancer Screening Test
  • 5.15 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
  • 5.16 Liquid Biopsy NGS Panels - Diverse Test Claims
  • 5.17 CMS Colon Cancer Screening Memo Bodes Well for Assays
  • 5.18 Natera Liquid Biopsy Test Coverage to Expand
  • 5.19 Freenome Closes Financing to Support Early Cancer Detection Trial
  • 5.20 C$2.6M Liquid Biopsy Initiative
  • 5.21 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
  • 5.22 Liquid Biopsy Shows Promise as Screen for Cancers
  • 5.23 Inivata launches RaDaR™ for the detection of residual disease and recurrence
  • 5.24 Liquid Biopsy Assay Detects 50+ Types of Cancer
  • 5.25 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
  • 5.26 Guardant Health Liquid Biopsy Expands Medicare Coverage
  • 5.27 Aethlon Medical Lands Grant for Exosome Isolation Device
  • 5.28 Biolidics to Develop Liquid Biopsy Breast Cancer Test
  • 5.29 Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
  • 5.30 Exact Sciences buys Genomic Health
  • 5.31 Multi-Gene Liquid Biopsy Breast Cancer Panel
  • 5.32 Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
  • 5.33 Thrive to Develop Earlier Detection of Multiple Cancer Types
  • 5.34 Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • 5.35 Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
  • 5.36 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
  • 5.37 Natera Commercializes Tumor Whole Exome Sequencing from Plasma
  • 5.38 Sienna Buys Liquid Biopsy & Exosome Isolation Technology

6 Profiles of Key Players

  • 6.1 Abbott Diagnostics
  • 6.2 AccuraGen Inc.
  • 6.3 Acuamark Diagnostics
  • 6.4 Admera Health, LLC
  • 6.5 Agena Bioscience, Inc.
  • 6.6 Agilent
  • 6.7 Amoy Diagnostics Co., Ltd.
  • 6.8 Anchor Dx
  • 6.9 ANGLE plc
  • 6.10 ApoCell, Inc.
  • 6.11 ArcherDx, Inc.
  • 6.12 Asuragen
  • 6.13 AVIVA Biosciences
  • 6.14 Baylor Miraca Genetics Laboratories
  • 6.15 Beckman Coulter, Inc.
  • 6.16 Becton, Dickinson and Company
  • 6.17 BGI Genomics Co. Ltd
  • 6.18 Bioarray Genetics
  • 6.19 Biocartis
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 bioMérieux Diagnostics
  • 6.24 Bioneer Corporation
  • 6.25 Bio-Rad Laboratories, Inc
  • 6.26 Bio-Techne
  • 6.27 Bioview
  • 6.28 Bolidics
  • 6.29 Boreal Genomics
  • 6.30 Caris Molecular Diagnostics
  • 6.31 CellMax Life
  • 6.32 Cepheid (now Danaher)
  • 6.33 Chronix Biomedical
  • 6.34 Circulogene
  • 6.35 Clinical Genomics
  • 6.36 Cynvenio
  • 6.37 Cytolumina Technologies Corp.
  • 6.38 CytoTrack
  • 6.39 Datar Cancer Genetics Limited
  • 6.40 Diagenode Diagnostics
  • 6.41 Diagnologix LLC
  • 6.42 Enzo Life Sciences, Inc.
  • 6.43 Epic Sciences
  • 6.44 Epigenomics AG
  • 6.45 Eurofins Scientific
  • 6.46 Exosome Diagnostics
  • 6.47 Exosome Sciences
  • 6.48 Fluidigm Corp
  • 6.49 Fluxion Biosciences
  • 6.50 Foundation Medicine
  • 6.51 Freenome
  • 6.52 GeneFirst Ltd.
  • 6.53 Genetron Health (Beijing) Co., Ltd.
  • 6.54 Genomic Health
  • 6.55 GILUPI Nanomedizin
  • 6.56 Grail, Inc.
  • 6.57 Guardant Health
  • 6.58 HansaBiomed
  • 6.59 HeiScreen
  • 6.60 Helomics
  • 6.61 Horizon Discovery
  • 6.62 iCellate
  • 6.63 Illumina
  • 6.64 Incell Dx
  • 6.65 Inivata
  • 6.66 Integrated Diagnostics
  • 6.67 Janssen Diagnostics
  • 6.68 MDNA Life SCIENCES, Inc.
  • 6.69 MDx Health
  • 6.70 Menarini Silicon Biosystems
  • 6.71 Millipore Sigma
  • 6.72 Miltenyi Biotec
  • 6.73 miR Scientific
  • 6.74 Molecular MD
  • 6.75 Myriad Genetics/Myriad RBM
  • 6.76 NantHealth, Inc.
  • 6.77 Natera
  • 6.78 NeoGenomics
  • 6.79 New Oncology
  • 6.80 Novogene Bioinformatics Technology Co., Ltd.
  • 6.81 Oncocyte
  • 6.82 OncoDNA
  • 6.83 Oxford Nanopore Technologies
  • 6.84 Perkin Elmer
  • 6.85 Personal Genome Diagnostics
  • 6.86 PrecisionMed
  • 6.87 Promega
  • 6.88 Qiagen Gmbh
  • 6.89 Quidel
  • 6.90 Rarecells SAS
  • 6.91 RareCyte
  • 6.92 Resolution Biosciences, Inc
  • 6.93 Roche Molecular Diagnostics
  • 6.94 Screencell
  • 6.95 Siemens Healthineers
  • 6.96 simfo GmbH
  • 6.97 Singlera Genomics Inc.
  • 6.98 SRI International
  • 6.99 Sysmex Inostics
  • 6.100 Tempus Labs, Inc.
  • 6.101 Thermo Fisher Scientific Inc.
  • 6.102 Thrive Earlier Detection
  • 6.103 Trovagene
  • 6.104 Volition

7 The Global Market for Liquid Biopsy Diagnostics

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Cancer - Overview
    • 7.2.1 Table - Global Market by Cancer
    • 7.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Cancer - Base Year
    • 7.2.4 Chart - Global Market by Cancer - End Year
    • 7.2.5 Chart - Global Market by Cancer - Share by Year
    • 7.2.6 Chart - Global Market by Cancer - Segments Growth
  • 7.3 Global Market by Usage - Overview
    • 7.3.1 Table - Global Market by Usage
    • 7.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Usage - Base Year
    • 7.3.4 Chart - Global Market by Usage - End Year
    • 7.3.5 Chart - Global Market by Usage - Share by Year
    • 7.3.6 Chart - Global Market by Usage - Segments Growth
  • 7.4 Global Market by Place - Overview
    • 7.4.1 Table - Global Market by Place
    • 7.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Place - Base Year
    • 7.4.4 Chart - Global Market by Place - End Year
    • 7.4.5 Chart - Global Market by Place - Share by Year
    • 7.4.6 Chart - Global Market by Place - Segments Growth
  • 7.5 Global Market by Marker - Overview
    • 7.5.1 Table - Global Market by Marker
    • 7.5.2 Chart - Global Market by Marker - Base/Final Year Comparison
    • 7.5.3 Chart - Global Market by Marker - Base Year
    • 7.5.4 Chart - Global Market by Marker - End Year
    • 7.5.5 Chart - Global Market by Marker - Share by Year
    • 7.5.6 Chart - Global Market by Marker - Segments Growth
  • 7.6 Global Market by Product - Overview
    • 7.6.1 Table - Global Market by Product
    • 7.6.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.6.3 Chart - Global Market by Product - Base Year
    • 7.6.4 Chart - Global Market by Product - End Year
    • 7.6.5 Chart - Global Market by Product - Share by Year
    • 7.6.6 Chart - Global Market by Product - Segments Growth

8 Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 8.1 Breast
    • 8.1.1 Table Breast - by Country
    • 8.1.2 Table Breast - by Country, Price
    • 8.1.3 Table Breast - by Country Volume
    • 8.1.4 Chart - Breast Growth
  • 8.2 Colorectal
    • 8.2.1 Table Colorectal - by Country
    • 8.2.2 Table Colorectal - by Country, Price
    • 8.2.3 Table Colorectal - by Country, Volume
    • 8.2.4 Chart - Colorectal Growth
  • 8.3 Cervical
    • 8.3.1 Table Cervical - by Country
    • 8.3.2 Table Cervical - by Country, Price
    • 8.3.3 Table Cervical - by Country, Volume
    • 8.3.4 Chart - Cervical Growth
  • 8.4 Lung
    • 8.4.1 Table Lung - by Country
    • 8.4.2 Table Lung - by Country, Price
    • 8.4.3 Table Lung - by Country, Volume
    • 8.4.4 Chart - Lung Growth
  • 8.5 Prostate
    • 8.5.1 Table Prostate - by Country
    • 8.5.2 Table Prostate - by Country, Price
    • 8.5.3 Table Prostate - by Country, Volume
    • 8.5.4 Chart - Prostate Growth
  • 8.6 Other
    • 8.6.1 Table Other - by Country
    • 8.6.2 Table Other - by Country, Price
    • 8.6.3 Table Other - by Country, Volume
    • 8.6.4 Chart - Other Growth

9 Global Liquid Biopsy Diagnostic Markets - by Usage

  • 9.1 Screening
    • 9.1.1 Table Screening - by Country
  • 9.2 Chart - Screening Growth
  • 9.3 Diagnostic
    • 9.3.1 Table Diagnostic - by Country
    • 9.3.2 Chart - Diagnostic Growth
  • 9.4 Therapy
    • 9.4.1 Table Therapy - by Country
    • 9.4.2 Chart - Therapy Growth
  • 9.5 Monitor
    • 9.5.1 Table Monitor - by Country
    • 9.5.2 Chart - Monitor Growth

10 Global Liquid Biopsy Diagnostic Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Lab Service
    • 10.2.1 Table Lab Service - by Country
    • 10.2.2 Chart - Lab Service Growth
  • 10.3 Lab Outpatient
    • 10.3.1 Table Lab Outpatient - by Country
    • 10.3.2 Chart - Lab Outpatient Growth
  • 10.4 Other Lab
    • 10.4.1 Table Other Lab - by Country
    • 10.4.2 Chart - Other Lab Growth

11 Global Liquid Biopsy Diagnostic Markets - by Marker

  • 11.1 Circulating Tumor Cell
    • 11.1.1 Table Circulating Tumor Cell - by Country
    • 11.1.2 Chart - Circulating Tumor Cell Growth
  • 11.2 Cell Free DNA
    • 11.2.1 Table Cell Free DNA - by Country
    • 11.2.2 Chart - Cell Free DNA Growth
  • 11.3 Vesicle
    • 11.3.1 Table Vesicle - by Country
    • 11.3.2 Chart - Vesicle Growth
  • 11.4 Other Marker
    • 11.4.1 Table Other Marker - by Country
    • 11.4.2 Chart - Other Marker Growth

12 Global Liquid Biopsy Diagnostic Markets - by Product

  • 12.1 Kits
    • 12.1.1 Table Kits - by Country
    • 12.1.2 Chart - Kits Growth
  • 12.2 Instruments
    • 12.2.1 Table Instruments - by Country
    • 12.2.2 Chart - Instruments Growth
  • 12.3 Service
    • 12.3.1 Table Service - by Country
    • 12.3.2 Chart - Service Growth

13 Appendices

  • 13.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

Table of Tables

  • Table 1 Market Players by Type
  • Table 2 Biopsy Sites
  • Table 3 Advantages of Liquid Biopsy in Screening Market
  • Table 4 Outlook - Phases of Liquid Biopsy Adoption by Year
  • Table 5 Five Factors Driving Growth
  • Table 6 Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 - Global Market by Region
  • Table 10 Global Market by Cancer
  • Table 11 Global Market by Usage
  • Table 12 Global Market by Place
  • Table 13 Global Market by Marker
  • Table 14 Global Market by Product
  • Table 15 Breast by Country
  • Table 16 Breast by Country Price
  • Table 17 Breast by Country Volume
  • Table 18 Colorectal by Country
  • Table 19 Colorectal by Country Price
  • Table 20 Colorectal by Country Volume
  • Table 21 Cervical by Country
  • Table 22 Cervical by Country Price
  • Table 23 Cervical by Country Volume
  • Table 24 Lung by Country
  • Table 25 Lung by Country Price
  • Table 26 Lung by Country Volume
  • Table 27 Prostate by Country
  • Table 28 Prostate by Country Price
  • Table 29 Prostate by Country Volume
  • Table 30 Other by Country
  • Table 31 Other by Country Price
  • Table 32 Other by Country Volume
  • Table 33 Screening by Country
  • Table 34 Diagnostic by Country
  • Table 35 Therapy by Country
  • Table 36 Monitor by Country
  • Table 37 Hospital Lab by Country
  • Table 38 Lab Service by Country
  • Table 39 Lab Outpatient by Country
  • Table 40 Other Lab by Country
  • Table 41 Circulating Tumor Cell by Country
  • Table 42 Cell Free DNA by Country
  • Table 43 Vesicle by Country
  • Table 44 Other Marker by Country
  • Table 45 Kits by Country
  • Table 46 Instruments by Country
  • Table 47 Service by Country
  • Table 48 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 Comparison of Liquid Biopsy Classes
  • Figure 4 Characteristics of Different Vesicle Types
  • Figure 5 Percentage of World Population Over 65
  • Figure 6 Global Market Regional Share Chart
  • Figure 7 Global Market by Cancer - Base vs. Final
  • Figure 8 Global Market by Cancer Base Year
  • Figure 9 Global Market by Cancer End Year
  • Figure 10 Cancer Share by Year
  • Figure 11 Cancer Segments Growth
  • Figure 12 Global Market by Usage - Base vs. Final
  • Figure 13 Global Market by Usage Base Year
  • Figure 14 Global Market by Usage End Year
  • Figure 15 Usage Share by Year
  • Figure 16 Usage Segments Growth
  • Figure 17 Global Market by Place - Base vs. Final
  • Figure 18 Global Market by Place Base Year
  • Figure 19 Global Market by Place End Year
  • Figure 20 Place Share by Year
  • Figure 21 Place Segments Growth
  • Figure 22 Global Market by Marker - Base vs. Final
  • Figure 23 Global Market by Marker Base Year
  • Figure 24 Global Market by Marker End Year
  • Figure 25 Marker Share by Year
  • Figure 26 Marker Segments Growth
  • Figure 27 Global Market by Product - Base vs. Final
  • Figure 28 Global Market by Product Base Year
  • Figure 29 Global Market by Product End Year
  • Figure 30 Product Share by Year
  • Figure 31 Product Segments Growth
  • Figure 32 Breast Growth
  • Figure 33 Colorectal Diagnostics Growth
  • Figure 34 Cervical Growth
  • Figure 35 Lung Growth
  • Figure 36 Prostate Growth
  • Figure 37 Other Growth
  • Figure 38 Screening Growth
  • Figure 39 Diagnostic Growth
  • Figure 40 Therapy Growth
  • Figure 41 Monitor Growth
  • Figure 42 Hospital Lab Growth
  • Figure 43 Lab Service Growth
  • Figure 44 Lab Outpatient Growth
  • Figure 45 Other Lab Growth
  • Figure 46 Circulating Tumor Cell Growth
  • Figure 47 Cell Free DNA Growth
  • Figure 48 Vesicle Growth
  • Figure 49 Other Marker Growth
  • Figure 50 Kits Growth
  • Figure 51 Instruments Growth
  • Figure 52 Service Growth
  • KKKKK